Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
CONCLUSIONS: This retrospective real-world population study revealed that CPS differentiated OS better than TPS in patients with advanced NSCLC with ICI monotherapy. Remarkably, this was driven by the performance of the TPS-/CPS+ subgroup, indicating that CPS may be a better predictive biomarker for ICI efficacy.PMID:37681219 | PMC:PMC10480627 | DOI:10.1016/j.jtocrr.2023.100532
Source: Clinical Lung Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Ezgi B Ulas Sayed M S Hashemi Ilias Houda Adem Kaynak Joris D Veltman Marieke F Fransen Teodora Radonic Idris Bahce Source Type: research
Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma
CONCLUSION: The RMM-I molecular subtype constituted the novel molecular characteristic subtype of LUAD, which complemented the existing pathological typing. More refined and accurate molecular subtypes provide help to reveal the mechanism of LUAD development. In addition, the RMM-I score offers a reliable tool for accurate prognosis of LUAD.PMID:37680151 | DOI:10.2174/0929867331666230901110629
Source: Current Medicinal Chemistry - September 8, 2023 Category: Chemistry Authors: Jiajing Wang Jianfeng Shu Source Type: research
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation
CONCLUSIONS: Endometrial cancer patients with MLH1 hypermethylation display significantly decreased survival and discrepant immunotherapy responses compared to patients with MLH1 mutated tumors, which was associated with differential mutational profiles, a more immune cold phenotype, and increased ER/PR expression in MLH1 hypermethylated tumors. Providers may consider early transition from single agent ICI to a multi-agent regimen or hormonal therapy for patients with MLH1 hypermethylated tumors.PMID:37683549 | DOI:10.1016/j.ygyno.2023.08.015
Source: Gynecologic Oncology - September 8, 2023 Category: Cancer & Oncology Authors: Michael D Toboni Sharon Wu Alex Farrell Joanne Xiu Jennifer R Ribeiro Matthew J Oberley Rebecca Arend Britt K Erickson Thomas J Herzog Premal H Thaker Matthew A Powell Source Type: research
Disfunction of communication among immune cells in minimal-deviation adenocarcinoma of the cervix as an immunotherapeutic opportunity
In this study, we conducted single-cell transcriptomic analyses of MDA samples (Ca) and adjacent normal tissues (PCa). The present study reveals the prevalence of dendritic cells (DCs) and T cells in the carcinoma (Ca) of mammary ductal adenocarcinoma (MDA), with DCs undergoing significant metabolic reprogramming and immune stress. Additionally, our findings demonstrate the crucial involvement of DCs and T cells in the pathogenesis and metastatic progression of MDA, as evidenced by single-cell transcriptomic profiling of MDA and HPV samples. This resource provides a more profound understanding of the indolent nature of MDA...
Source: International Immunopharmacology - September 8, 2023 Category: Allergy & Immunology Authors: Hui Zhang Chunhua Liu Xiaoqian Zhai Qianqian Zhang Yao Zhou Hu Huang Mingde Ding Qiang Shi Yan Liu Ying Tang Guanghai Liu Hongmei Wang Source Type: research
A review of immune modulators and immunotherapy in infectious diseases
Mol Cell Biochem. 2023 Sep 8. doi: 10.1007/s11010-023-04825-w. Online ahead of print.ABSTRACTThe human immune system responds to harmful foreign invaders frequently encountered by the body and employs defense mechanisms to counteract such assaults. Various exogenous and endogenous factors play a prominent role in maintaining the balanced functioning of the immune system, which can result in immune suppression or immune stimulation. With the advent of different immune-modulatory agents, immune responses can be modulated or regulated to control infections and other health effects. Literature provides evidence on various immu...
Source: Molecular and Cellular Biochemistry - September 8, 2023 Category: Biochemistry Authors: P Sangeetha Vijayan Joseph Xavier Mohanan Parayanthala Valappil Source Type: research
Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease
CONCLUSION: CHRNA6 may be associated with immune infiltration in LUSC and affects patient prognosis and immunotherapeutic response by regulating immune cells and immune pathways. In addition, adavosertib may be a potential drug for the treatment of LUSC.PMID:37680128 | DOI:10.2174/1381612829666230901143203
Source: Current Pharmaceutical Design - September 8, 2023 Category: Drugs & Pharmacology Authors: Fengyu Zhang Meidi Zhang Xin Yuan Yulian Tao Ju Wang Source Type: research
Anti ‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Int J Oncol. 2023 Nov;63(5):122. doi: 10.3892/ijo.2023.5570. Epub 2023 Sep 8.ABSTRACTImmune checkpoint inhibitors (ICIs) play a significant anti‑tumor role in the management of non‑small cell lung cancer. The most broadly used ICIs are anti‑programmed death 1 (PD‑1), anti‑programmed cell death‑ligand 1, and anti‑cytotoxic T lymphocyte‑associated antigen‑4 monoclonal antibody. Compared with traditional chemotherapy, ICIs have the advantages of greater efficiency and more specific targeting. However, the resulting immune‑related adverse events limit the clinical application of ICIs, especially checkpoint ...
Source: International Journal of Oncology - September 8, 2023 Category: Cancer & Oncology Authors: Xiao Hu Jin Ren Qianfei Xue Rumei Luan Dongyan Ding Jie Tan Xin Su Junling Yang Source Type: research
A review of immune modulators and immunotherapy in infectious diseases
Mol Cell Biochem. 2023 Sep 8. doi: 10.1007/s11010-023-04825-w. Online ahead of print.ABSTRACTThe human immune system responds to harmful foreign invaders frequently encountered by the body and employs defense mechanisms to counteract such assaults. Various exogenous and endogenous factors play a prominent role in maintaining the balanced functioning of the immune system, which can result in immune suppression or immune stimulation. With the advent of different immune-modulatory agents, immune responses can be modulated or regulated to control infections and other health effects. Literature provides evidence on various immu...
Source: Molecular and Cellular Biochemistry - September 8, 2023 Category: Biochemistry Authors: P Sangeetha Vijayan Joseph Xavier Mohanan Parayanthala Valappil Source Type: research
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles
CONCLUSION: For this real-world population of patients with FoundationOneCDx solid tumor profiles in the routine course of clinical care, clinically significant findings were reported for approximately half of patients with genomic results.PMID:37682776 | DOI:10.1093/oncolo/oyad251
Source: The Oncologist - September 8, 2023 Category: Cancer & Oncology Authors: Andreas M Heilmann Jonathan W Riess Margaret McLaughlin-Drubin Richard S P Huang Meghann Hjulstrom James Creeden Brian M Alexander Rachel L Erlich Source Type: research
A near-infrared fluorescence-enhancing plasmonic biosensing microarray identifies soluble PD-L1 and ICAM-1 as predictive checkpoint biomarkers for cancer immunotherapy
Biosens Bioelectron. 2023 Aug 23;240:115633. doi: 10.1016/j.bios.2023.115633. Online ahead of print.ABSTRACTSensitive and accurate biomarker-driven assay guidance has been widely adopted to identify responsive patients for immune checkpoint blockade (ICB) therapy to impede disease progression and extend survival. However, most current assays are invasive, requiring surgical pathology specimens and only informing monochronic information. Here, we report a multiplexed enhanced fluorescence microarray immunoassay (eFMIA) based on a nanostructured gold nanoisland substrate (AuNIS), which macroscopically amplifies near-infrared...
Source: Biosensors and Bioelectronics - September 8, 2023 Category: Biotechnology Authors: Zhijun Lin Mengyao Liu Wei Xing Fenghua Wang Hongxia Zhang Xiaoli Wei Hans Schmitthenner Xi Xie Xiaojun Xia Jiang Yang Source Type: research
Cyclometalated iridium(III) complexes induce immunogenic cell death in HepG2 cells via paraptosis
Bioorg Chem. 2023 Sep 6;140:106837. doi: 10.1016/j.bioorg.2023.106837. Online ahead of print.ABSTRACTImmunotherapy has been shown to provide superior antitumor efficacy by activating the innate immune system to recognize, attack and eliminate tumor cells without seriously harming normal cells. Herein, we designed and synthesized three new cyclometalated iridium(III) complexes (Ir1, Ir2, Ir3) then evaluated their antitumor activity. When co-incubated with HepG2 cells, the complex Ir1 localized in the lysosome, where it induced paraptosis and endoplasmic reticulum stress (ER stress). Notably, Ir1 also induced immunogenic cel...
Source: Bioorganic Chemistry - September 8, 2023 Category: Chemistry Authors: Jiaxin Liao Yuqing Zhang Minying Huang Zhijun Liang Yao Gong Ben Liu Yuling Li Jiaxi Chen Wei Wu Zunnan Huang Jing Sun Source Type: research
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles
CONCLUSION: For this real-world population of patients with FoundationOneCDx solid tumor profiles in the routine course of clinical care, clinically significant findings were reported for approximately half of patients with genomic results.PMID:37682776 | DOI:10.1093/oncolo/oyad251
Source: The Oncologist - September 8, 2023 Category: Cancer & Oncology Authors: Andreas M Heilmann Jonathan W Riess Margaret McLaughlin-Drubin Richard S P Huang Meghann Hjulstrom James Creeden Brian M Alexander Rachel L Erlich Source Type: research
Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease
CONCLUSION: CHRNA6 may be associated with immune infiltration in LUSC and affects patient prognosis and immunotherapeutic response by regulating immune cells and immune pathways. In addition, adavosertib may be a potential drug for the treatment of LUSC.PMID:37680128 | DOI:10.2174/1381612829666230901143203
Source: Current Pharmaceutical Design - September 8, 2023 Category: Drugs & Pharmacology Authors: Fengyu Zhang Meidi Zhang Xin Yuan Yulian Tao Ju Wang Source Type: research
